a study of apalutamide in participants with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy

Conditions: Prostatic Neoplasms

Summary: the purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (adt) before and after radical prostatectomy (rp) with pelvic lymph node dissection (plnd) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pcr) rate and metastasis-free survival (mfs) as compared to placebo plus adt.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the prostate * high-risk disease defined by a total gleason sum score greater than equal to (\>=) 4+3 (=grade groups \[gg\] 3 5) and \>=1 of the following 4 criteria: a) any combination of gleason score 4+3 (= 3) and gleason score 8 (4+4 or 5+3) in \>= 6 systematic cores (with \>=1 core gleason score 8 \[4+4 or 5+3\] included); b) any combination of gleason score 4+3 (=gg 3) and gleason score 8 (4+4 or 5+3) in \>=3 systematic cores and prostate-specific antigen (psa) \>=20 ng/ml (with \>= 1 core gleason score 8 \[4+4 or 5+3\] included); c) gleason score \>=9 (=gg 5) in at least 1 systematic or targeted core; d) at least 2 systematic or targeted cores with continuous gleason score \>=8 (=gg 4), each with \> 80 percent (%) involvement * candidate for radical prostatectomy with pelvic lymph node dissection as per the investigator * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * contraceptive use by male participants (and female partners of male participants enrolled in the study who are of childbearing potential or are pregnant) should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies * able to receive androgen deprivation therapy (adt) for at least 13 months exclusion criteria: * distant metastasis based on conventional imaging (clinical stage m1). nodal disease below the iliac bifurcation (clinical stage n1) is not an exclusion. diagnosis of distant metastasis (clinical m stage; m0 versus m1a, m1b, m1c) and pelvic nodal disease (clinical n stage; n1 versus n0) will be assessed by central radiological review. participants are considered eligible only if the central radiological review confirms clinical stage m0 * (a) prior treatment with androgen receptor antagonists; (b) treatment with gonadotropin-releasing hormone analog (gnrha) prior to informed consent form (icf) signature * history of prior systemic or local therapy for prostate cancer, including pelvic radiation for prostate cancer * use of any investigational agent less than or equals to (\<=)4 weeks prior to randomization or any therapeutic procedure for prostate cancer at any time * major surgery \<=4 weeks prior to randomization * any of the following within 12 months prior to first dose of study drug: severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (example, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias or new york heart association class ii to iv heart disease; uncomplicated deep vein thrombosis is not considered exclusionary